The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation

Letters16 February 2010The Net Clinical Benefit of Warfarin Anticoagulation in Atrial FibrillationVikram Budhraja, MDVikram Budhraja, MDFrom Lincoln Medical Center, Fayetteville, TN 37334.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-4-201002160-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Current guidelines from the American College of Cardiology/American Heart Association recommend that warfarin be given to patients with atrial fibrillation on the basis of stroke risk. This strategy maximizes stroke reduction only if the effect of warfarin is uniform across all risk factors. Singer and colleagues (1) present data that suggest otherwise. Their subgroup analysis found that men and women with atrial fibrillation have markedly different relative risk reductions when treated with warfarin (adjusted relative risk reduction, about 34% in men vs. 55% in women). Formal testing for treatment by covariate interaction (not reported by the authors) ...Reference1. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297-305. [PMID: 19721017] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Vikram Budhraja, MDAffiliations: From Lincoln Medical Center, Fayetteville, TN 37334.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Daniel E. Singer , Yuchiao Chang , Margaret C. Fang , Leila H. Borowsky , Niela K. Pomernacki , Natalia Udaltsova , and Alan S. Go The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Daniel E. Singer , Yuchiao Chang , and Alan S. Go The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Henry Bussey Metrics Cited byEvolution of and Evidence-Practice Gaps in Antithrombotic Management of Atrial Fibrillation Patients After Percutaneous Coronary InterventionTime‐trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF‐STENT RegistryComparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation 16 February 2010Volume 152, Issue 4Page: 265KeywordsAtrial fibrillationConflicts of interestHeartHypertensionMedical risk factorsRelative riskStrokeTreatment guidelines ePublished: 16 February 2010 Issue Published: 16 February 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...